-- HAV remained patent and host-cell remodeling was observed in non-human primate model -- -- Preclinical study represents milestone in the development of small-diameter HAVs for use in cardiac bypass ...
DURHAM, N.C., Dec. 31, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment ...
– Performance of HAVs produced in the LUNA200™ commercial-scale system demonstrated efficacy that is similar to prior HAV performance in dialysis access trials – – 83% secondary patency observed at 12 months ...
Copyright © 2015 - 2021 Lifecarenews.in
